See more : EonX Technologies Inc. (EONX.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Carl Zeiss Meditec AG (CZMWY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Carl Zeiss Meditec AG, a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Solarvest BioEnergy Inc. (SVS.V) Income Statement Analysis – Financial Results
- Makalot Industrial Co., Ltd. (1477.TW) Income Statement Analysis – Financial Results
- Companhia Estadual de Geração e Transmissão de Energia Elétrica – CEEE-GT (EEEL3.SA) Income Statement Analysis – Financial Results
- Global Business Travel Group, Inc. (GBTG) Income Statement Analysis – Financial Results
- China Carbon Neutral Development Group Limited (1372.HK) Income Statement Analysis – Financial Results
Carl Zeiss Meditec AG (CZMWY)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers products and solutions for the diagnosis and treatment of eye diseases; and systems and consumables for cataract, retinal, and refractive surgeries. It serves practicing ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The Microsurgery segment offers visualization solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, dental and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.07B | 2.09B | 1.90B | 1.65B | 1.34B | 1.46B | 1.28B | 1.19B | 1.09B | 1.04B | 909.26M | 906.45M | 861.88M | 758.79M | 676.68M | 640.09M | 600.19M | 569.70M | 390.56M | 0.00 |
| Cost of Revenue | 977.50M | 883.54M | 775.24M | 679.57M | 589.94M | 627.44M | 570.47M | 533.16M | 508.82M | 500.38M | 420.88M | 418.62M | 400.51M | 343.96M | 317.96M | 317.80M | 296.75M | 274.18M | -206.80M | -171.42M |
| Gross Profit | 1.09B | 1.21B | 1.13B | 967.21M | 745.52M | 831.88M | 710.39M | 656.73M | 579.55M | 539.68M | 488.37M | 487.82M | 461.36M | 414.84M | 358.73M | 322.29M | 303.44M | 295.52M | 597.37M | 171.42M |
| Gross Profit Ratio | 52.69% | 57.71% | 59.26% | 58.73% | 55.83% | 57.00% | 55.46% | 55.19% | 53.25% | 51.89% | 53.71% | 53.82% | 53.53% | 54.67% | 53.01% | 50.35% | 50.56% | 51.87% | 152.95% | 0.00% |
| Research & Development | 343.09M | 375.81M | 291.37M | 232.07M | 218.80M | 173.31M | 159.63M | 145.79M | 123.41M | 111.96M | 99.75M | 97.32M | 93.45M | 84.22M | 72.36M | 63.46M | 61.96M | 59.24M | -38.30M | -31.76M |
| General & Administrative | 111.01M | 83.78M | 77.88M | 60.75M | 56.32M | 57.68M | 49.83M | 48.09M | 46.48M | 49.19M | 41.79M | 42.32M | 40.98M | 40.28M | 37.25M | 32.37M | 32.27M | 32.13M | 23.61M | 0.00 |
| Selling & Marketing | 458.20M | 420.28M | 360.18M | 303.23M | 292.84M | 336.23M | 303.82M | 289.56M | 255.33M | 247.95M | 226.13M | 214.29M | 204.04M | 187.14M | 162.80M | 150.65M | 141.79M | 134.40M | -74.88M | -67.86M |
| SG&A | 569.21M | 504.06M | 438.06M | 363.98M | 349.16M | 393.91M | 353.65M | 337.65M | 301.81M | 297.14M | 267.92M | 256.61M | 245.01M | 227.42M | 200.05M | 183.02M | 174.06M | 166.53M | -74.88M | -67.86M |
| Other Expenses | 176.33M | 0.00 | 1.29M | -2.45M | 0.00 | 0.00 | -15.00K | 993.00K | 0.00 | 0.00 | 0.00 | 17.00K | 2.69M | -2.57M | -418.00K | -16.63M | 12.70M | -495.00K | 0.00 | 0.00 |
| Operating Expenses | 1.09B | 878.63M | 730.72M | 593.60M | 567.97M | 567.23M | 513.26M | 484.43M | 425.21M | 409.09M | 367.67M | 353.95M | 338.46M | 311.27M | 271.98M | 229.84M | 248.72M | 225.27M | -113.19M | -99.62M |
| Cost & Expenses | 2.07B | 1.76B | 1.51B | 1.27B | 1.16B | 1.19B | 1.08B | 1.02B | 934.03M | 909.47M | 788.55M | 772.57M | 738.98M | 655.23M | 589.94M | 547.64M | 545.47M | 499.45M | -319.99M | -271.04M |
| Interest Income | 23.27M | 29.05M | 13.25M | 1.56M | 1.46M | 1.80M | 977.00K | 937.00K | 1.08M | 1.30M | 1.93M | 5.18M | 3.02M | 4.52M | 5.86M | 5.28M | 9.77M | 9.71M | 2.47M | 0.00 |
| Interest Expense | 29.42M | 1.92M | 9.59M | 9.37M | 27.89M | 8.21M | 2.66M | 2.70M | 3.60M | 2.78M | 2.95M | 6.59M | 6.08M | 7.17M | 5.88M | 6.00M | 5.71M | 6.39M | 3.37M | 0.00 |
| Depreciation & Amortization | 132.77M | 74.06M | 69.77M | 61.58M | 60.43M | 48.37M | 31.28M | 24.24M | 20.23M | 19.16M | 17.95M | 18.72M | 17.90M | 18.94M | 20.97M | 16.37M | 12.73M | 11.82M | 10.77M | 9.12M |
| EBITDA | 403.06M | 501.88M | 482.85M | 410.00M | 267.03M | 286.44M | 213.12M | 206.96M | 165.78M | 135.15M | 135.44M | 168.40M | 140.16M | 126.99M | 109.79M | 100.98M | 94.17M | 94.33M | 59.70M | 280.16M |
| EBITDA Ratio | 19.51% | 24.02% | 25.38% | 24.90% | 20.00% | 19.63% | 16.44% | 17.39% | 15.31% | 12.99% | 14.90% | 19.07% | 16.26% | 16.74% | 16.23% | 15.78% | 15.69% | 16.56% | 84.69% | 0.00% |
| Operating Income | 0.00 | 327.14M | 413.08M | 348.42M | 206.61M | 238.07M | 179.34M | 182.72M | 146.37M | 115.99M | 117.48M | 154.18M | 122.90M | 103.57M | 86.74M | 76.08M | 67.83M | 70.36M | 48.09M | 35.73M |
| Operating Income Ratio | 0.00% | 15.66% | 21.71% | 21.16% | 15.47% | 16.31% | 14.00% | 15.36% | 13.45% | 11.15% | 12.92% | 17.01% | 14.26% | 13.65% | 12.82% | 11.89% | 11.30% | 12.35% | 12.31% | 0.00% |
| Total Other Income/Expenses | 240.87M | 85.43M | 31.47M | -11.86M | 19.37M | -8.21M | -157.00K | 5.83M | -4.41M | -14.27M | -2.95M | -6.59M | -6.72M | -2.69M | -3.73M | 2.53M | 7.52M | 5.75M | -2.52M | 0.00 |
| Income Before Tax | 240.87M | 412.56M | 403.49M | 339.05M | 178.72M | 229.86M | 179.18M | 188.56M | 141.96M | 101.72M | 114.54M | 147.59M | 116.18M | 100.88M | 82.98M | 78.62M | 75.73M | 76.11M | 45.56M | 0.00 |
| Income Before Tax Ratio | 11.66% | 19.75% | 21.20% | 20.59% | 13.38% | 15.75% | 13.99% | 15.85% | 13.04% | 9.78% | 12.60% | 16.28% | 13.48% | 13.29% | 12.26% | 12.28% | 12.62% | 13.36% | 11.67% | 0.00% |
| Income Tax Expense | 60.71M | 120.56M | 107.58M | 101.53M | 55.30M | 69.28M | 52.95M | 52.78M | 41.99M | 36.16M | 35.38M | 48.47M | 39.79M | 28.61M | 23.34M | 23.51M | 19.49M | 26.47M | 15.86M | 0.00 |
| Net Income | 178.73M | 290.40M | 293.91M | 236.28M | 122.39M | 159.76M | 126.46M | 134.45M | 98.33M | 62.30M | 74.95M | 92.13M | 71.87M | 66.91M | 54.85M | 50.54M | 54.05M | 47.76M | 26.69M | 0.00 |
| Net Income Ratio | 8.65% | 13.90% | 15.45% | 14.35% | 9.16% | 10.95% | 9.87% | 11.30% | 9.03% | 5.99% | 8.24% | 10.16% | 8.34% | 8.82% | 8.11% | 7.90% | 9.01% | 8.38% | 6.83% | 0.00% |
| EPS | 1.99 | 3.25 | 3.29 | 2.64 | 1.37 | 1.79 | 1.41 | 1.57 | 1.21 | 0.77 | 0.92 | 1.13 | 0.88 | 0.82 | 0.68 | 0.62 | 0.66 | 0.61 | 0.82 | 0.54 |
| EPS Diluted | 1.99 | 3.25 | 3.29 | 2.64 | 1.37 | 1.79 | 1.41 | 1.57 | 1.21 | 0.77 | 0.92 | 1.13 | 0.88 | 0.82 | 0.68 | 0.62 | 0.66 | 0.61 | 0.82 | 0.54 |
| Weighted Avg Shares Out | 89.74M | 89.44M | 89.44M | 89.44M | 89.44M | 89.44M | 89.44M | 85.59M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 77.97M | 32.52M | 32.52M |
| Weighted Avg Shares Out (Dil) | 89.74M | 89.44M | 89.44M | 89.44M | 89.44M | 89.44M | 89.44M | 85.59M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 81.31M | 77.97M | 32.52M | 32.52M |
Carl Zeiss: Why I Am So Positive
Carl Zeiss Meditec is a high-quality MedTech company with a strong market position, low debt, and significant long-term upside potential despite current macroeconomic challenges. The company's fundamentals remain robust, with impressive free cash flow, rising shareholder equity, and a history...
My 3 Favorite European Stocks To Diversify Your Portfolio
Here is an emphasis on the importance of diversification in US-based investment portfolios to mitigate risks and enhance returns. The recommendation is to focus on sectors with strong growth potential, such as technology, defense, and media. These picks have solid...
Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows
Carl Zeiss Meditec has seen a 30%+ decline due to earnings and margin drops, but remains a strong market leader with significant long-term upside. Despite current underperformance, the company's strategic R&D investments and growing recurring revenue position it well for...
Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript
Carl Zeiss Meditec AG (OTCPK:CZMWF) Q3 2024 Results Conference Call August 6, 2024 4:30 AM ET Company Participants Sebastian Frericks - Director of Investor Relations Markus Weber - CEO & Chairman of Management Board Justus Wehmer - CFO & Member...
Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside
Carl Zeiss Meditec has underperformed in the medtech field, but its long-term appeal remains intact. The company reported a decline in revenue and margins in the first half of 2023/2024, mainly due to challenges in the Chinese market. Despite near-term...
Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript
Carl Zeiss Meditec AG (OTCPK:CZMWF) Q2 2024 Earnings Conference Call May 8, 2024 4:30 AM ET Company Participants Sebastian Frericks - Head, IR Markus Weber - CEO Justus Wehmer - CFO Conference Call Participants Oliver Reinberg - Kepler Cheuvreux Oliver...
Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential
Carl Zeiss Meditec has seen a significant increase in stock performance, up over 29% in less than 3 months. The company has shown strong top-line growth but a decline in EBIT and EBIT margin. Challenges include a decline in volume,...
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany , Dec. 15, 2023 /PRNewswire/ -- Carl Zeiss Meditec AG announced today that it has entered into an...
Carl Zeiss Meditec: Premiums Are Proven To Be Dicey In This Market
Carl Zeiss Meditec has seen a decline in its stock price, along with other high-valued companies, due to the commoditization of premium stocks. The company has impressive products, high gross margins, and strong financial performance compared to its competitors in...
Carl Zeiss Meditec: One Of The Highest Premiums I'll Accept
Carl Zeiss Meditech is a subsidiary of Carl Zeiss AG and manufactures tools for eye examination and medical lasers. The company has a strong financial performance with high gross and net margins. Despite being heavily focused on the German market,...
Source: https://incomestatements.info
Category: Stock Reports